Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)

NCT03683251 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03683251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Recruiting
Start date
September 20, 2018
Completion date
December 31, 2029
Enrollment
1,000 (estimated)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration